127406-56-8Relevant articles and documents
A three step continuous flow synthesis of the biaryl unit of the HIV protease inhibitor Atazanavir
Dalla-Vechia, Luciana,Reichart, Benedikt,Glasnov, Toma,Miranda, Leandro S. M.,Kappe, C. Oliver,De Souza, Rodrigo O. M. A.
, p. 6806 - 6813 (2013)
The development of multistep continuous flow reactions for the synthesis of important intermediates for the pharmaceutical industry is still a significant challenge. In the present contribution the biaryl-hydrazine unit of Atazanavir, an important HIV protease inhibitor, was prepared in a three-step continuous flow sequence in 74% overall yield. The synthesis involved Pd-catalyzed Suzuki-Miyaura cross-coupling, followed by hydrazone formation and a subsequent hydrogenation step, and additionally incorporates a liquid-liquid extraction step.
Synthesis of phosphoramidates: A facile approach based on the C-N bond formation via Ir-catalyzed direct C-H amidation
Kim, Hyunwoo,Park, Juhyeon,Kim, Jeung Gon,Chang, Sukbok
, p. 5466 - 5469 (2014)
A new synthetic route to phosphoramidates by intermolecular C-H amidation is presented. Substrates with assorted directing groups were activated by an iridium-based catalyst system and reacted with a number of phosphoryl azides, executing efficient phosphoramidate synthesis via C-N bond formations. (Chemical Equation Presented).
Calix[6]arene derivatives selectively functionalized at alternate sites on the smaller rim with 2-phenylpyridine and 2-fluorenylpyridine substituents to provide deep cavities
Zeng, Xianshun,Batsanov, Andrei S.,Bryce, Martin R.
, p. 9589 - 9594 (2006)
The synthesis is described of calix[6]arene derivatives 4, 9, and 14 functionalized at alternate sites on the smaller rim with 4′-(pyrid- 2″-yl)phenylmethoxy, (6′-phenylpyrid-3′-ylmethoxy), and {6′-[2-(9,9-di-n-hexylfluorenyl)]pyrid-3′-ylmethoxy} substitu
UV Light Generation and Challenging Photoreactions Enabled by Upconversion in Water
Pfund, Bj?rn,Steffen, Debora M.,Schreier, Mirjam R.,Bertrams, Maria-Sophie,Ye, Chen,B?rjesson, Karl,Wenger, Oliver S.,Kerzig, Christoph
, p. 10468 - 10476 (2020)
Sensitized triplet-triplet annihilation (sTTA) is the most promising mechanism for pooling the energy of two visible photons, but its applications in solution were so far limited to organic solvents, with a current maximum of the excited-singlet state energy of 3.6 eV. By combining tailor-made iridium complexes with naphthalenes, we demonstrate blue-light driven upconversion in water with unprecedented singlet-state energies approaching 4 eV. The annihilators have outstanding excited-state reactivities enabling challenging photoreductions driven by sTTA. Specifically, we found that an aryl-bromide bond activation can be achieved with blue photons, and we obtained full conversion for the very energy-demanding decomposition of a persistent ammonium compound as typical water pollutant, not only with a cw laser but also with an LED light source. These results provide the first proof-of-concept for the usage of low-power light sources for challenging reactions employing blue-to-UV upconversion in water and pave the way for the further development of sustainable light-harvesting applications.
Synthesis, thermal and optical properties of a novel bis(2-(4-dicyanovinylphenyl)pyridinato-N,C2)iridium(acetylacetonate)
Altin?l?ek, Nuray,Tavasli, Mustafa,Aydemir, Murat,Abay, Bahattin,Monkman, Andrew P.
, p. 102 - 106 (2016)
Bis(2-(4-formylphenyl)pyridinato-N,C2)iridium(acetylacetonate) (5) was subjected to a Knoevenagel reaction with malononitrile in dichloromethane in the presence of catalytic amount of pyrrolidine. This gave successfully a novel bis(2-(4-dicyanovinylphenyl
Insights into the Catalytic Activity of [Pd(NHC)(cin)Cl] (NHC=IPr, IPrCl, IPrBr) Complexes in the Suzuki–Miyaura Reaction
Izquierdo, Frédéric,Zinser, Caroline,Minenkov, Yury,Cordes, David B.,Slawin, Alexandra M. Z.,Cavallo, Luigi,Nahra, Fady,Cazin, Catherine S. J.,Nolan, Steven P.
, p. 601 - 611 (2018)
The influence of C4,5-halogenation on palladium N-heterocyclic carbene complexes and their activity in the Suzuki–Miyaura reaction were investigated. Two [Pd(NHC)(cin)Cl] complexes bearing IPrCl and IPrBr ligands (IPr=1,3-bis(2,6-diisopropyl-phenyl)imidazol-2-ylidene; cin=cinnamyl) were synthesized. After determining the electronic and steric properties of these ligands, their properties were compared to those of [Pd(IPr) (cin)Cl]. The three palladium complexes were studied by using DFT calculations to delineate their behavior in the activation step leading to the putative 12-electron active catalyst. Experimentally, their catalytic activity in the Suzuki–Miyaura reaction involving a wide range of coupling partners (30 entries) at low catalyst loading was studied.
Desulfonative Suzuki–Miyaura Coupling of Sulfonyl Fluorides
Bahadori, Maryam,Brykczyńska, Daria,Chatelain, Paul,Moran, Joseph,Muller, Cyprien,Rowley, Christopher N.,Sau, Abhijit
supporting information, p. 25307 - 25312 (2021/10/25)
Sulfonyl fluorides have emerged as powerful “click” electrophiles to access sulfonylated derivatives. Yet, they are relatively inert towards C?C bond forming transformations, notably under transition-metal catalysis. Here, we describe conditions under which aryl sulfonyl fluorides act as electrophiles for the Pd-catalyzed Suzuki–Miyaura cross-coupling. This desulfonative cross-coupling occurs selectively in the absence of base and, unusually, even in the presence of strong acids. Divergent one-step syntheses of two analogues of bioactive compounds showcase the expanded reactivity of sulfonyl fluorides to encompass both S?Nu and C?C bond formation. Mechanistic experiments and DFT calculations suggest oxidative addition occurs at the C?S bond followed by desulfonation to form a Pd-F intermediate that facilitates transmetalation.
N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME
-
Page/Page column 181, (2021/02/12)
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidin-2-one compounds (also referred to herein as "FRPPO compounds"), that, inter alia, inhibit glutaminyl-peptide cyclotransferase-like (isoQC) enzyme and/or glutaminyl-peptide cyclotransferase (QC) enzyme (e.g., inhibit or reduce or block the activity or function of isoQC and/or QC enzyme). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit isoQC and/or QC enzyme; to treat disorders that are ameliorated by the inhibition of isoQC and/or QC enzyme; to treat cancer, atherosclerosis, fibrotic diseases, infectious diseases, Alzheimer's disease, etc.
